Nonlipogenic ABCA1 Inducers (NLAI) for Alzheimer's Disease Validated in a Mouse Model Expressing Human APOE3/APOE4
Ganga Reddy Velma,Megan S. Laham,Cutler Lewandowski,Ana C. Valencia-Olvera,Deebika Balu,Annabelle Moore,Martha Ackerman-Berrier,Pavel Rychetsky,Christopher Penton,Soumya Reddy Musku,Anandhan Annadurai,Maha Ibrahim Sulaiman,Nina Ma,Gregory R J Thatcher
DOI: https://doi.org/10.1021/acs.jmedchem.4c00733
IF: 8.039
2024-08-30
Journal of Medicinal Chemistry
Abstract:Therapeutics enhancing apolipoprotein (APOE) positive function are a priority, because APOE4 is the major genetic risk factor for Alzheimer's disease (AD). The function of APOE, the key constituent of lipoprotein particles that transport cholesterol and lipids in the brain, is dependent on lipidation by ABCA1, a cell-membrane cholesterol transporter. ABCA1 transcription is regulated by liver X receptors (LXR): agonists have been shown to increase ABCA1, often accompanied by unwanted lipogenesis...
chemistry, medicinal
What problem does this paper attempt to address?